QUIDEL CORP /DE/

Quidel Corp /DE/ operates in the In Vitro & In Vivo Diagnostic Substances SIC universe, developing rapid diagnostic solutions for infectious diseases, cardiovascular markers, and women's health that serve hospitals, reference labs, and clinicians seeking fast, reliable answers at the point of care. Its core product families include antigen tests, molecular diagnostics, and companion assay platforms that blend immunoassay and molecular techniques to help public health agencies and commercial providers respond quickly to outbreaks and chronic illness trends. While the company has not reported a more recent 8-K since December 1999, the regulatory backdrop remains entrenched in FDA clearance pathways, CLIA oversight, and global supply-chain scrutiny, so investors should keep an eye on compliance, reimbursement shifts, and reimbursement pressures that could materially affect adoption and pricing. CIK 353569. For the latest disclosures, view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025